Evidence map›Paper›PMID 39208260›Full record

ArticlePloS one2024

Picroside II suppresses chondrocyte pyroptosis through MAPK/NF-κB/NLRP3 signaling pathway alleviates osteoarthritis.

Fanchen Wang, Jiacong Xiao, Miao Li, Qi He, Xintian Wang, Zhaofeng Pan, Shaocong Li, Haibin Wang, Chi Zhou

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fanchen WangFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.ORCID 0000-0001-9824-641X
Jiacong XiaoFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Miao LiFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Qi HeFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xintian WangFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Zhaofeng PanThe Laboratory of Orthopedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shaocong LiFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Haibin WangFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Chi ZhouDepartment of Orthopedic Surgery, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.ORCID 0000-0003-1905-9494

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPicroside II (P-II) is the main bioactive constituent of Picrorhiza Kurroa, a traditional Chinese herb of interest for its proven anti-inflammatory properties. Its beneficial effects have been noted across several physiological systems, including the nervous, circulatory, and digestive, capable of treating a wide range of diseases. Nevertheless, the potential of Picroside II to treat osteoarthritis (OA) and the mechanisms behind its efficacy remain largely unexplored.

aimThis study aims to evaluate the efficacy of Picroside II in the treatment of osteoarthritis and its potential molecular mechanisms.

methodsIn vitro, we induced cellular inflammation in chondrocytes with lipopolysaccharide (LPS) and subsequently treated with Picroside II to assess protective effect on chondrocyte. We employed the Cell Counting Kit-8 (CCK-8) assay to assess the impact of Picroside II on cell viability and select the optimal Picroside II concentration for subsequent experiments. We explored the effect of Picroside II on chondrocyte pyroptosis and its underlying molecular mechanisms by qRT-PCR, Western blot (WB) and immunofluorescence. In vivo, we established the destabilization of the medial meniscus surgery to create an OA mouse model. The therapeutic effects of Picroside II were then assessed through Micro-CT scanning, Hematoxylin-eosin (H&E) staining, Safranin O-Fast Green (S&F) staining, immunohistochemistry and immunofluorescence.

resultsIn in vitro studies, toluidine blue and CCK-8 results showed that a certain concentration of Picroside II had a restorative effect on the viability of chondrocytes inhibited by LPS. Picroside II notably suppressed the expression levels of caspase-1, IL-18, and IL-1β, which consequently led to the reduction of pyroptosis. Moreover, Picroside II was shown to decrease NLRP3 inflammasome activation, via the MAPK/NF-κB signaling pathway. In vivo studies have shown that Picroside II can effectively reduce subchondral bone destruction and osteophyte formation in the knee joint of mice after DMM surgery.

conclusionsOur research suggests that Picroside II can inhibit chondrocyte pyroptosis and ameliorate osteoarthritis progression by modulating the MAPK/NF-κB signaling pathway.

Indexed as

ChondrocytesCinnamatesIridoid GlucosidesNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinOsteoarthritisPyroptosisAnimalsLipopolysaccharidesMaleMAP Kinase Signaling SystemMiceMice, Inbred C57BLSignal TransductionCinnamatesIridoid GlucosidesLipopolysaccharidesNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousepicroside II

Identifiers

PMID39208260
PMCPMC11361613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.